The independent effect of drug resistance on T cell activation in HIV infection

AIDS

Volumn 20, Issue 5, 2006, Pages 691-699

  Hunt, Peter W ^a,e   Deeks, Steven G ^a   Bangsberg, David R ^a   Moss, Andrew ^a   Sinclair, Elizabeth ^b   Liegler, Teri ^a   Bates, Michael ^c   Tsao, Gabriel ^b   Lampiris, Harry ^a   Hoh, Rebecca ^a   Martin, Jeffrey N ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Drug resistance; HIV; T cell activation

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; HLA DR ANTIGEN; PROTEINASE INHIBITOR; RNA;

ADULT; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; VIREMIA; VIRUS RESISTANCE; WILD TYPE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RNA, VIRAL; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; VIREMIA;

EID: 33646883620     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000216369.30948.18     Document Type: Article

References (57)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133:35-39.
2. Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hisa A, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999; 159:1771-1776.
3. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130:570-577.
4. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F43.
5. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
6. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
7. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
8. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-1044.
9. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-197.
10. Ledergerber B, Lundgren JD, Fusco GP, Weber R, Wit F, Castelli F, et al. Factors affecting CD4 count slope in patients with stable viral load following three class virologic failure: the PLATO collaboration. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2003 [abstract 1461b].
11. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
12. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologie and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-1335.
13. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201-207.
14. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, McClure HM, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003; 18:441-452.
15. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 2003; 4:49-54.
16. Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346-355.
17. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
18. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:332-340.
19. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
20. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, et al. Immune activation set-point during early HIV infection predicts subsequent CD44- T cell changes independent of viral load. Blood 2004; 104:942-947.
21. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400-3406.
22. Pitrak DL, Bolanos J, Hershow R, Novak RM. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001; 15:1317-1319.
23. Meroni L, Varchetta S, Manganaro D, Gatti N, Riva A, Monforte A, et al. Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors. J Infect Dis 2002; 186:143-144.
24. Hazenberg MD, Otto SA, Wit FW, Lange JM, Hamann D, Miedema F. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS 2002; 16:1287-1289.
25. Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis 2003; 187:1027-1037.
26. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-323.
27. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999; 94:1021-1027.
28. Phenix BN, Angel JB, Mandy F, Kravcik S, Parato K, Chambers KA, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:559-567.
29. Estaquier J, Lelievre JD, Petit F, Brunner T, Moutouh-De Parseval L, Richman DD, et al. Effects of antiretroviral drugs on human immunodeficiency virus type 1- induced CD4(+) T-cell death. J Virol 2002; 76:5966-5973.
30. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-124.
31. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
32. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, et al. Interruption of individual therapeutic drug classes in adults with multi-drug resistant HIV-1. J Infect Dis 2005; 192:1537-1544.
33. Iyer SB, Hultin LE, Zawadzki JA, Davis KA, Giorgi JV. Quantitation of CD38 expression using QuantiBRITE beads. Cytometry 1998; 33:206-212.
34. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol 2000; 38:1113-1120.
35. Carbone J, Gil J, Benito JM, Navarro J, Muñóz- Fernández A, Bartolomé J, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000; 14:2823-2829.
36. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, et al. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol 2003; 77:6743-6752.
37. Moore C, John M, James I, Mallal S. The Influence of Host HLA on Antiretroviral Drug Resistance Mutation in HIV-1. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 554-T].
38. Tenorio AR, Smith KY, Kuritzkes DR, Sha BE, Donoval B, Young R, et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr 2003; 34:491-496.
39. Price DA, Scullard G, Oxenius A, Barganza R, Beddows SA, Kazmi S, et al. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol 2003; 77:6041-6049.
40. Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312-321.
41. Amendola A, Lombardi G, Oliverio S, Colizzi V, Piacentini M. HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by 'tissue' transglutaminase expression and prevented by cyclosporin A. FEBS Lett 1994; 339:258-264.
42. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992; 176:1099-1106.
43. Capobianchi MR. Induction of lymphomonocyte activation by HIV-1 glycoprotein gp120. Possible role in AIDS pathogenesis. J Biolog Regulators Homeostatic Agents 1996; 10:83-91.
44. Finco O, Nuti S, De Magistris MT, Mangiavacchi L, Aiuti A, Forte P, et al. Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4. Eur J Immunol 1997; 27:1319-1324.
45. Liegler TJ, Stites DP. HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes. J Acquir Immune Defic Syndr 1994; 7:340-348.
46. Schols D, De Clercq E. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J Virol 1996; 70:4953-4960.
47. Tuosto L, Montani MS, Lorenzetti S, Cundari E, Moretti S, Lombardi G, et al. Differential susceptibility to monomeric HIV gp120-mediated apoptosis in antigen-activated CD4+ T cell populations. Eur J Immunol 1995; 25:2907-2916.
48. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497-500.
49. James CO, Huang MB, Khan M, Garcia-Barrio M, Powell MD, Bond VC. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004; 78:3099-3109.
50. Aldrovandi GM, Gao L, Bristol G, Zack JA. Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol 1998; 72:7032-7039.
51. Chen YL, Trono D, Camaur D. The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol 1998; 72:3178-3184.
52. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988; 53:55-67.
53. Kido H, Kamoshita K, Fukutomi A, Katunuma N. Processing protease for gp160 human immunodeficiency virus type I envelope glycoprotein precursor in human T4+ lymphocytes. Purification and characterization. J Biol Chem 1993; 268:13406-13413.
54. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD, et al. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 2004; 78:3429-3435.
55. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999; 5:997-103.
56. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201-207.
57. Francke S, Orosz CG, Hayes KA, Mathes LE. Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function. Antimicrob Agents Chemother 2000; 44:1900-1905.